Vitae Pharmaceuticals (VTAE) Breathtaking Antipsoriatic Potential; FedEx (FDX) Profit Above Forecasts


Shares of Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE) soared more than 50% in after-hours trading Wednesday as the company said that its orally active RORγt inhibitor VTP-43742 demonstrated a clear signal of efficacy and was well tolerated – in a mid-stage trial – in patients with psoriasis, a chronic autoimmune disorder affecting the skin.

VTAE stock finished the regular session at $4.11, down $0.34 (or -7.64%), and 1,589,732 of its shares exchanged hands during the day, a large increase in activity versus its average volume (3m) of 358,857

Vitae Pharmaceuticals, a clinical-stage biotechnology company, has 21.87M Shares Outstanding, Market Capitalization (intraday) of $89.89M and VTAE stock 52-week range is between $4.08 and $18.71 per share.



The price of FedEx Corporation (NYSE:FDX) stock climbed over 5% in the extended session Wednesday after the company delivered in its financial results quarterly profit and revenue numbers above Wall Street analysts’ expectations, driven by the growth in e-commerce

For its third quarter fiscal 2016, FedEx posted revenue of $12.7 billion, an 8.5% increase year over year, and non-GAAP net income of $692 million, or $2.51 per diluted share, compared to non-GAAP net income of $628 million, or $2.18 per diluted share in the same quarter the prior year, surpassing the Capital IQ Consensus estimate of $2.35 earnings per share on revenues of $12.38 billion for the period

FDX stock closed at $144.27, up $1.20 (or +0.84%), with a total volume of 2,573,159 shares traded

FedEx, which provides transportation, e-commerce, and business services in the U.S. and internationally, has 275.62M Shares Outstanding, Market Capitalization (intraday) of $39.76B and FDX stock one-year range is from $119.71 and $185.19 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at